Business UpdateMay 27, 2026, 04:31 PM
ImageneBio CEO to Present at Jefferies Global Healthcare Conference
AI Summary
ImageneBio, Inc. announced that its CEO, Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM EDT. Management will also hold one-on-one meetings. The company is a clinical-stage biotechnology firm focused on immunological, autoimmune, and inflammatory diseases, with its lead program IMG-007 in Phase 2b for atopic dermatitis and planning a Phase 2 study for alopecia areata.
Key Highlights
- ImageneBio CEO Kristin Yarema, Ph.D., to present at Jefferies Global Healthcare Conference.
- Presentation scheduled for Thursday, June 4, 2026, at 12:50 PM EDT.
- Management will also participate in one-on-one meetings at the conference.
- Webcast available and archived for 90 days on ImageneBio's IR website.
- ImageneBio is a clinical-stage biotech developing therapeutics for immunological, autoimmune, and inflammatory diseases.
- Lead program IMG-007 is an anti-OX40 monoclonal antibody with a 5-week half-life.
- Currently conducting a Phase 2b clinical trial of IMG-007 in moderate-to-severe atopic dermatitis.
- Plans to initiate a Phase 2 study in alopecia areata after completing a proof-of-concept trial.
Price Impact
More from IMA